Avenue

Clearwater Analytics Announces Pricing of Secondary Offering of Class A Common Stock

Retrieved on: 
Thursday, March 9, 2023
RBC Capital Markets, Credit Suisse, Security (finance), Clearwater Analytics, NYSE, SVB Securities, Form, Avenue, Morgan Stanley, Bookrunner, Sale, Software as a service, Goldman Sachs, Form S-3, Oppenheimer, Wells Fargo, Oppenheimer Holdings, Telephone, J.P. Morgan & Co., Prospectus

BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced the pricing of its underwritten secondary public offering of its Class A common stock priced at a price to the public of $15.00 per share.

Key Points: 
  • BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced the pricing of its underwritten secondary public offering of its Class A common stock priced at a price to the public of $15.00 per share.
  • The offering consists of 13,000,000 shares of Class A common stock to be sold by certain affiliates of Welsh, Carson, Anderson & Stowe (collectively, the "Selling Stockholders").
  • The Company will not receive any proceeds from the sale of the Company's Class A common stock by the Selling Stockholders.
  • The Company's Class A common stock is listed on the New York Stock Exchange under the ticker symbol "CWAN."

Clearwater Analytics Announces Launch of Secondary Offering of Class A Common Stock

Retrieved on: 
Wednesday, March 8, 2023
Welsh, Carson, Anderson & Stowe, Security (finance), Clearwater Analytics, NYSE, Form, Avenue, Sale, Software as a service, Form S-3, Telephone, J.P. Morgan & Co., Prospectus

BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 13,000,000 shares of the Company's Class A common stock.

Key Points: 
  • BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 13,000,000 shares of the Company's Class A common stock.
  • The Company is conducting a resale of Class A common stock on behalf of certain affiliates of Welsh, Carson, Anderson & Stowe (collectively, the "Selling Stockholders").
  • The Company will not receive any proceeds from the sale of the Company's Class A common stock by the Selling Stockholders.
  • The Company's Class A common stock is listed on the New York Stock Exchange under the ticker symbol "CWAN."

Vistra to Create "Vistra Vision," a Leading Zero-Carbon Generation and Retail Platform, Through the Acquisition of Energy Harbor

Retrieved on: 
Monday, March 6, 2023
Nuclear Regulatory Commission, Federal Energy Regulatory Commission, Citigroup, RBC Capital Markets, Adjustment, Dechert, Latham & Watkins, Webcast, Nuveen, Hart–Scott–Rodino Antitrust Improvements Act, Share repurchase, FirstEnergy, NYSE, Carbon, Plant, Growth, United States Department of Justice Civil Division, Justice, Avenue Capital Group, Partnership, ERCOT, Morgan, Lewis & Bockius, Risk management, Electricity, LLP, VST, PJM, Nuclear energy, Financial adviser, Renewable energy, Security (finance), Bank, Retail, Avenue, Vistra Corp

IRVING, Texas, March 6, 2023 /PRNewswire/ -- Today, Vistra Corp. (NYSE: VST) announced that it has executed a definitive agreement with Energy Harbor Corp., pursuant to which Energy Harbor will merge with and into a newly-formed subsidiary of Vistra. The transaction will combine Energy Harbor's nuclear and retail businesses with Vistra's nuclear and retail businesses and Vistra Zero renewables and storage projects under a newly-formed subsidiary holding company, referred to generally as "Vistra Vision." This combination creates a leading integrated retail electricity and zero-carbon generation company with the second-largest competitive nuclear fleet in the country, along with a growing renewables and energy storage portfolio. The agreement has been approved by both companies' boards of directors. Sufficient stockholder approval for the transaction has been committed through support agreements signed by a majority of the Energy Harbor stockholders.

Key Points: 
  • Consideration to Energy Harbor for this combination includes $3 billion cash and a 15% ownership interest in Vistra Vision; in addition, Vistra Vision will assume ~$430 million of net debt from Energy Harbor.
  • Vistra will own 85% of Vistra Vision as well as 100% of the entities holding its remaining conventional generation assets, referred to generally as "Vistra Tradition."
  • Sufficient stockholder approval for the transaction has been committed through support agreements signed by a majority of the Energy Harbor stockholders.
  • Burke concluded, "We look forward to welcoming the Energy Harbor generation and retail teams in Ohio and Pennsylvania to Vistra.

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

Retrieved on: 
Thursday, March 2, 2023
Safety, Walking, DSM-IV codes, Spinal and bulbar muscular atrophy, NFE2L2, Cell death, Patient, Spinocerebellar ataxia, Choking, Speech, Literature, Therapy, Anterior grey column, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Muscle atrophy, Oxidative stress, Orphan, SBMA, Food, AR, Pharmaceutical industry, Avenue

“The license for AJ201 brings a cutting-edge asset into Avenue’s pipeline that is the lead molecule in the clinic to treat Kennedy’s Disease, a debilitating rare neuromuscular disorder.

Key Points: 
  • “The license for AJ201 brings a cutting-edge asset into Avenue’s pipeline that is the lead molecule in the clinic to treat Kennedy’s Disease, a debilitating rare neuromuscular disorder.
  • SBMA is a rare, inherited, X-linked genetic neuromuscular disease primarily affecting men.
  • The weakening of the bulbar muscles affects chewing, speech and swallowing, with patients prone to choking or inhaling foods or liquids, resulting in airway infection.
  • This study aims to evaluate the safety and clinical response of AJ201 in patients suffering from SBMA.

Asphalt Construction Project Earns Granite a NAPA Quality in Construction Award

Retrieved on: 
Tuesday, February 14, 2023
Transport, Other Construction & Property, Construction & Property, Urban Planning, Building Systems, Other Transport, County, NAPA, GVA, Quality, Annual general meeting, NYSE, City, Avenue, Coachella Valley, HMA, Granite Construction, Road

On Wednesday, February 8th, Granite’s (NYSE:GVA) Desert Cities region won a National Asphalt Pavement Association (NAPA) 2022 Quality in Construction Award for excellence in the construction of an asphalt pavement during the association’s 68th Annual Meeting.

Key Points: 
  • On Wednesday, February 8th, Granite’s (NYSE:GVA) Desert Cities region won a National Asphalt Pavement Association (NAPA) 2022 Quality in Construction Award for excellence in the construction of an asphalt pavement during the association’s 68th Annual Meeting.
  • The winning project, the Avenue 52 and Calhoun Street reconstruction in Coachella, California, was built for the County of Riverside Transportation Department.
  • All contractors’ projects earning a Quality in Construction award are measured against best practices designed to live up to that commitment,” said 2022 NAPA Chairman James A. Mitchell.
  • “Earning the Quality in Construction Award demonstrates that Granite Construction Inc. has met or exceeded these rigorous standards.”

TopBloc announces expansion of its Office of Customer Experience

Retrieved on: 
Monday, January 30, 2023
Commercial software, CIO, Oracle, Associated Global Systems, Avenue, CFO, Customer experience, CHRO, Retail, Avenues: The World School, HCM, Human resources, MedicAnimal, Senior, Management, NetSuite

CHICAGO, Jan. 30, 2023 /PRNewswire-PRWeb/ -- TopBloc today announced the expansion of its Office of Customer Experience and its intention to expand its offerings to include advisory support and services, including enterprise systems assessment, strategy support, and road mapping. TopBloc's Office of Customer Experience will focus on supporting Workday prospects and customers alike by providing comprehensive advice that enables them to make strategic decisions and maximize the impact of their Workday investment. The expansion of this function marks another milestone for TopBloc as the company continues to enhance its offerings as a comprehensive Workday Services Partner.

Key Points: 
  • "TopBloc's Office of Customer Experience is made up of accomplished executives with real and recent customer experiences that are focused on helping TopBloc's current and prospective customers maximize their Workday investments.
  • In conjunction with the announced expansion of the Office of Customer Experience, TopBloc shared that several new executives will be joining the organization:
    David Sun is TopBloc's new Senior Vice President of Customer Experience, focused on the Office of the CFO.
  • Peter Gong will be joining TopBloc as Vice President of Customer Experience, focused on the Office of the CIO.
  • Lynn Cohen is TopBloc's new Vice President of Customer Experience, focused on the Office of the CHRO.

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

Retrieved on: 
Tuesday, January 31, 2023
Peripheral nervous system, Telephone, Attention, Special-purpose acquisition company, Form S-3, Avenue, Sale, Form, Prospectus, Exercise, Therapy, Security (finance)

The Company issued 1,940,299 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering.

Key Points: 
  • The Company issued 1,940,299 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering.
  • The private placement warrants will be exercisable immediately subject to registration and will have a 3-year term from the initial exercise date.
  • Aggregate gross proceeds to the Company of both transactions were approximately $3.25 million.
  • The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No.

Visit Hungary Announces New Hotel Openings in Budapest for 2023

Retrieved on: 
Monday, January 30, 2023
Food, UNESCO, Autograph Collection, Avenue, Business development, Architecture, Business, Investment, Marriott International, W Hotels, Culture, Hotel, Nightclub

BUDAPEST, Hungary, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Hungary is known for its culture, fine gastronomy, old-world wines, natural beauty, and new attractions.

Key Points: 
  • BUDAPEST, Hungary, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Hungary is known for its culture, fine gastronomy, old-world wines, natural beauty, and new attractions.
  • "Budapest experienced an invigorating rebound in 2022," explains Ivan Ljubinkovic, Head of Business Development at Visit Hungary.
  • W Budapest Hotel, Marriott group - Andrássy Avenue, Budapest (Opening 2023)
    W Hotels Worldwide, part of Marriott International, debuts the iconic W Hotels brand in Hungary, opening W Budapest.
  • Dorothea Hotel, Autograph Collection, Marriott group - Vörösmarty Square, Budapest (Opening July 2023)
    The newly constructed Dorothea Hotel Autograph Collection opens in July 2023 in central Budapest.

Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Retrieved on: 
Friday, January 27, 2023
Peripheral nervous system, Telephone, Attention, Special-purpose acquisition company, Form S-3, Avenue, Sale, Form, Prospectus, Exercise, Therapy, Security (finance)

The private placement warrants will be exercisable immediately subject to registration and will have a 3-year term from the initial exercise date.

Key Points: 
  • The private placement warrants will be exercisable immediately subject to registration and will have a 3-year term from the initial exercise date.
  • Aggregate gross proceeds to the Company of both transactions are expected to be approximately $3.25 million.
  • The transactions are expected to close on or about January 31, 2023, subject to the satisfaction of customary closing conditions.
  • The entire transaction has been priced at the market under Nasdaq rules.

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

Retrieved on: 
Monday, December 19, 2022
Biotechnology, Fortification, Fortress Biotech, Therapy, Drug development, Research, Business, CFO, Audit committee, University School, University, New York University Stern School of Business, Pharmaceutical industry, Avenue, Science

MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors.

Key Points: 
  • MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors.
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman and Chief Executive Officer, said, “We are delighted to welcome Lucy back to Fortress in a new capacity, as a member of our Board of Directors.
  • Lucy is well-versed in the Fortress business model and well equipped to immediately add strategic value at the Board level.
  • From February 2012 to June 2017, she was Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc.